Fig. 4From: Platelet-rich plasma inhibits Adriamycin-induced inflammation via blocking the NF-κB pathway in articular chondrocytesPRP inhibits doxorubicin-induced inflammation via blocking NF-κB pathway. ATDC5 cells were treated with PRP and doxorubicin for 24 h. A Western blot to exam the protein levels of p-IκBα, IκBα, p-NF-κB 65, NF-κB 65, and β-ACTIN. B–D Quantitation of the immunoblots. At least three independent experiments were performed. E BMM cells were treated with PRP and doxorubicin for 24 h. Western blot results of the protein levels of p-NF-κB, NF-κB, and β-actin. F Quantitation of the immunoblots. G Real-time PCR to detect mRNA levels of IL-6, IL-1β, and TNF-α. *p < 0.05 vs control of the same doxorubicin treatment; #p < 0.05 vs vehicle of the same TGF β treatmentBack to article page